Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Cardiovascular Disease

In brief

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).

Key facts

Study ID

NCT04270760

Run by

Amgen

People needed

281

Starts

2020-07-28

Expected to finish

2022-11-08

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 80 years
• Lipoprotein (a) > 150 nmol/L
• Evidence of atherosclerotic cardiovascular disease

You may not qualify if…

• Severe renal dysfunction
• History or clinical evidence of hepatic dysfunction
• Malignancy within the last 5 years
• Currently receiving, or less than 3 months at Day 1 since receiving > 200 mg/day Niacin

Where it is running

• Westside Medical Associates of Los Angeles — Beverly Hills, California, United States
• Excel Medical Clinical Trials — Boca Raton, Florida, United States
• Piedmont Healthcare — Atlanta, Georgia, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Johns Hopkins — Baltimore, Maryland, United States
• New York University — New York, New York, United States
• Mount Sinai Hospital — New York, New York, United States
• Columbia University Medical Center — New York, New York, United States
• Crossroads Clinical Research Inc — Mooresville, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Baylor College of Medicine — Houston, Texas, United States
• Protenium Clinical Research — Hurst, Texas, United States
• Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
• Core Research Group Pty Ltd — Milton, Queensland, Australia
• Monash Medical Centre — Clayton, Victoria, Australia
• Linear Clinical Research Limited — Nedlands, Western Australia, Australia
• Dr Heart Pty Ltd — Woolloongabba, Australia
• LMC Clinical Research Incorporated — Brampton, Ontario, Canada
• LMC Clinical Research Incorporated Thornhill — Concord, Ontario, Canada
• Ecogene-21 — Chicoutimi, Quebec, Canada
• Research Institute of McGill University Health Center - Glen Site — Montreal, Quebec, Canada
• Clinique des Maladies Lipidiques de Quebec Incorporated — Québec, Quebec, Canada
• Aarhus Universitetshospital — Aarhus N, Denmark
• Herlev Gentofte Hospital — Herlev, Denmark
• Regionshospitalet Viborg — Viborg, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.